OVERVIEW
Oragenics, Inc. is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies and a primary focus on commercialization. The corporate strategy is to bring products to market as quickly as possible and use the proceeds to further the development and commercialization of the remaining technologies. In addition to marketed products based on the ProBiora3 technology, the Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health. Oragenics has developed platform technologies with respect to its products, thereby creating a potential pipeline of future products, which the Company expects to develop.
|
 |
A BRIEF HISTORY
Dr. Jeffery Hillman began his basic research into the concept of Replacement Therapy for preventing dental caries or cavities in the late 1970's at the Forsyth Dental Center in Boston. He transferred his research to the University of Florida College of Dentistry in 1992. There, he continued to pursue the development of a genetically engineered strain of Streptococcus mutans that could both prevent cavities and replace the bodies natural caries-causing strains of S .mutans.
Dr. Hillman and Dr. Robert Zahradnick founded Oragenics at the end of 1996 to commercialize the fruits of 25 years of research. |
|
